In contrast, the co-occurrence of the STK11 and KEAP1 mutations appear to drive resistance to ICIs, even in tumors with a high tumor mutational burden (TMB), by shaping an immunosuppressive metabolic environment that impairs immune cell activation [65]. The gene discussed is STK11; the disease is neoplasm.